Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain
Authors, Journal, Affiliations, Type, DOI
- Kuan Ken Lee, Ryan Wereski, David Lowe, Rachel O'Brien, and co-authors for the TARGET-CTCA Investigators; lead site British Heart Foundation Centre of Research Excellence, University of Edinburgh.
- 14 hospitals across the United Kingdom.
- The New England Journal of Medicine, 2026;395:1794-1804 (November 5, 2026 issue).
- Type: multicentre, open-label, event-driven, randomized controlled trial with blinded endpoint assessment.
- DOI: 10.1056/NEJMoa2608903. ClinicalTrials.gov: NCT03952351.
- Funded by the British Heart Foundation.
Overview
TARGET-CTCA tested whether early outpatient CT coronary angiography (CTCA) improves outcomes in patients who present with suspected acute coronary syndrome, have myocardial infarction ruled out, and are at intermediate risk by high-sensitivity troponin. Among 3,170 participants across 14 UK hospitals, CTCA-guided care did not reduce the composite of myocardial infarction or cardiac death at a median 3.0 years: 7.1% versus 7.3% (adjusted hazard ratio 0.95, 95% CI 0.73–1.23; P=0.71). CTCA was performed in 92.1% of the intervention arm and identified obstructive disease in 22.6%, yet the trial found no outcome benefit despite increased antiplatelet and statin use. The result argues against routine CTCA as a strategy to alter hard outcomes in this troponin-defined intermediate-risk group, while leaving open its diagnostic and triage roles.
Keywords
Acute coronary syndrome, CT coronary angiography, high-sensitivity cardiac troponin, intermediate risk, chest pain, myocardial infarction, preventive therapy, randomized controlled trial
Key Takeaways
Background and Rationale
- Acute chest pain accounts for 5–10% of emergency department visits; accelerated pathways using high-sensitivity troponin safely discharge many patients after MI is ruled out.
- Patients with intermediate troponin concentrations (above the low-risk threshold but below the sex-specific 99th percentile) have about twice the prevalence of coronary artery disease on CTCA and a tenfold higher one-year risk of MI or cardiac death than those with very low troponin.
- Guidelines recommend considering CTCA or noninvasive stress imaging in intermediate-risk patients, but no trial had shown that either investigation changes clinical outcomes.
Methods
- Adults ≥18 years presenting to an emergency department or acute medical assessment unit with suspected ACS; MI ruled out; maximum high-sensitivity cardiac troponin I or T >5 ng/L and below the sex-specific 99th percentile upper reference limit.
- Randomized 1:1 to outpatient CTCA-guided care plus standard care, or standard care alone; stratified by site, age (<70/≥70), sex and known coronary disease.
- CTCA was to be performed within 4 weeks using a 64-slice or higher scanner; results were reported per Society of Cardiovascular Computed Tomography guidance and communicated to the patient, primary care physician and treating clinicians.
- Reports recommended statin therapy for mild disease and antiplatelet plus statin therapy for moderate nonobstructive or obstructive disease; patients with obstructive disease or important noncardiac findings were offered an outpatient cardiology consultation.
- Primary outcome: composite of myocardial infarction (Fourth Universal Definition) or death from a cardiac cause.
- Secondary outcomes included clinical events, participant-reported outcomes, process measures and cost-effectiveness.
Participants
- 3,170 participants enrolled September 2019 to May 2023; median age 61 years (IQR 53–70); 30.2% women.
- 88.7% presented with chest discomfort; 17.5% had prior MI and 15.1% prior angina; 29.1% were taking an antiplatelet and 43.4% a statin at randomization.
- Mean HEART score 3.5±1.4; 49.7% had a HEART score >3. Median GRACE score 91.
- Median time from presentation to randomization 6 days.
Trial Intervention and Care
- CTCA was performed in 1,462 of 1,587 participants (92.1%), at a median of 22 days after randomization.
- CT findings: normal coronary arteries 31.8%, nonobstructive disease 42.5%, obstructive disease 22.6%; proximal LAD disease 9.0%, left main 0.8%, three-vessel disease 2.9%.
- Noncardiac findings in 42.2%; clinically significant noncardiac findings in 10.7%.
- At 90 days, antiplatelet use was 42.4% versus 32.8% and statin use 63.4% versus 48.5%; revascularization by end of trial 6.2% versus 4.9%.
- In the standard-care arm, nontrial CTCA was performed in 2.2% within 90 days and 6.5% by trial end.
Primary Outcome
- Myocardial infarction or cardiac death: 112 participants (7.1%) with CTCA versus 116 (7.3%) with standard care; adjusted hazard ratio 0.95 (95% CI 0.73–1.23; P=0.71).
- Results were consistent in competing-risk, 2-year, landmark, per-protocol and post hoc analyses.
- Event rates by CT finding in the intervention arm: 2.2% with normal arteries, 6.4% with nonobstructive disease and 11.5% with obstructive disease.
Secondary Outcomes
- Myocardial infarction 5.9% versus 6.3% (adjusted hazard ratio 0.92, 95% CI 0.69–1.22); cardiac death 1.4% versus 1.7% (0.83, 0.48–1.45); cardiovascular death 2.0% versus 2.1% (0.95, 0.58–1.54).
- Death from any cause 4.6% versus 6.1% (adjusted hazard ratio 0.74, 95% CI 0.54–1.00); noncardiovascular death 2.6% versus 4.0% (0.63, 0.43–0.93). These were not adjusted for multiplicity and do not support causal inference.
- Return visit for suspected ACS 40.3% versus 38.0%; unscheduled revascularization 2.4% versus 2.7%; major bleeding 0.4% versus 0.2%.
- CTCA-related adverse events in 7 participants (0.4%), all mild allergic reactions or contrast-associated acute kidney injury.
Subgroups
- The effect was consistent across sex, age, known coronary disease, preventative therapy, troponin assay and troponin concentration.
- By HEART score, CTCA appeared to favor low-risk participants (hazard ratio 0.58, 95% CI 0.35–0.98) and not intermediate- or high-risk participants (1.11, 0.81–1.50); the interaction was not adjusted for multiplicity and the trial was not designed to test it.
Interpretation
- The trial does not support routine CTCA as a strategy to reduce hard cardiac events after MI is ruled out, despite a high rate of coronary disease detection and increased preventive therapy.
- The absence of benefit may reflect a population already receiving contemporary secondary prevention, a low absolute event rate, and the possibility that CTCA changes management without changing the events that matter.
- The ongoing FAST-CCTA trial is testing CTCA in emergency-department patients with HEART score >3 and may clarify the risk-score subgroup.
Limitations of the Document
- The observed primary-event rate was lower than projected; the confidence interval is compatible with a 27% relative reduction to a 23% relative increase, so a modest benefit or harm cannot be excluded.
- Only about half the participants were intermediate risk by HEART score, despite all being intermediate risk by troponin.
- Most participants were men (69.8%), and the sex-specific troponin threshold classifies fewer women as intermediate risk.
- A substantial proportion had known coronary disease or were already on preventive therapy, which may have reduced the incremental benefit of CTCA.
- Conducted entirely in the UK, where baseline use of functional and anatomical imaging is low; the results may not transfer to health systems with different imaging practice.
- The trial tested a strategy of CTCA-guided care, not CTCA as a diagnostic test in isolation.
Key Concepts Mentioned
- concepts/CT-Coronary-Angiography-in-Acute-Chest-Pain — the strategy tested and its evidence base
- concepts/ACS-Management — acute coronary syndrome pathways and secondary prevention
- concepts/ASCVD-Risk-Assessment — risk stratification and preventive therapy thresholds
- concepts/Dyslipidemia-Management — statin initiation after coronary disease detection
Key Entities Mentioned
- entities/Acute-Coronary-Syndrome — the presenting syndrome and its definitions
- entities/Chronic-Coronary-Disease — the downstream management framework for nonobstructive and obstructive disease
Wiki Pages Updated
wiki/sources/TARGET-CTCA-NEJM-2026.md— created (this file)wiki/concepts/CT-Coronary-Angiography-in-Acute-Chest-Pain.md— createdwiki/concepts/ACS-Management.md— updated with the post-rule-out imaging evidencewiki/concepts/ASCVD-Risk-Assessment.md— updated with the troponin-based risk stratumwiki/wikiindex.md— updatedwiki/sourceindex.md— updated